Lexicon Pharma (LXRX) Misses Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.01 -1.47%
Revenue Growth %: -86.1%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -86.1%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $320 thousand versus the consensus estimate of $133.33 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Pfizer reafffirms 2026 guidance after CFO transition announcement
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
